Cybin Newsroom

Cybin Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 19, 2024 17:35 ET

CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86

Moomoo NewsNov 19, 2024 07:33 ET

Optimistic Buy Rating for Cybin: Promising CYB003 Phase 2 Results and Market Potential

TipRanksNov 19, 2024 07:02 ET

Cybin Analyst Ratings

BenzingaNov 18, 2024 12:13 ET

Cybin Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 14, 2024 11:11 ET

Cybin Analyst Ratings

BenzingaNov 14, 2024 11:04 ET

A. G. P. Initiates Cybin(CYBN.US) With Buy Rating, Announces Target Price $25

Moomoo NewsNov 14, 2024 07:34 ET

CCORF Maintains Cybin(CYBN.US) With Buy Rating, Cuts Target Price to $86

Moomoo NewsNov 14, 2024 07:34 ET

Cybin's Promising Growth in the Psychedelic Sector Justifies Buy Rating

TipRanksNov 4, 2024 09:36 ET

Strong Buy Rating for Cybin Inc. on Promising Clinical Advances and Strategic Management Positioning

TipRanksSep 24, 2024 04:18 ET

Cybin Is Maintained at Buy by Canaccord Genuity

Dow JonesSep 23, 2024 11:23 ET

Cybin Analyst Ratings

BenzingaSep 23, 2024 11:13 ET

Cybin Analyst Ratings

BenzingaAug 23, 2024 07:27 ET

Cybin's Promising Psychedelic Treatments Bolster Buy Rating and $5 Price Target

TipRanksAug 23, 2024 06:18 ET

Cybin Analyst Ratings

BenzingaJul 31, 2024 08:26 ET

Cybin Analyst Ratings

BenzingaJun 21, 2024 12:32 ET

Cybin Analyst Ratings

BenzingaMay 16, 2024 13:12 ET

Cybin's CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating

TipRanksMar 14, 2024 07:25 ET

Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations

TipRanksMar 13, 2024 11:40 ET

Cybin Analyst Ratings

BenzingaMar 13, 2024 11:32 ET